To analyze the signaling pathways required for killer cell induction by agonist antibody, relapsed AML cells were co-treated with agonist antibody and chemical inhibitors of Phosphatidylinositol-3-kinase (PI-3K) or Mitogen-activated protein kinase (MAPK) signaling pathways. The gene discussed is WNK2; the disease is acute myeloid leukemia.